SCHEMBL21802103

SCHEMBL21802103

O=C1c2cc([N+](=O)[O-])cnc2OC[C@H]2C[C@H](F)CN12

nearest known ligand 0.48

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALPL P05186 16/20 0.48
ALDH1A1 P00352 2/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
IDO1 P14902 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21801956 0.87 ALPL (0.49) ALPLALDH1A1MAPK1HTTIDO1
SCHEMBL21802113 0.87 ALPL (0.49) ALPLALDH1A1MAPK1HTTIDO1
SCHEMBL21801957 0.87 ALPL (0.49) ALPLALDH1A1MAPK1HTTIDO1
SCHEMBL21801977 0.85 ALPL (0.51) ALPLALDH1A1MAPK1HTT
SCHEMBL21802085 0.82 ALPL (0.45) ALPL
SCHEMBL21801941 0.81 ALPL (0.51) ALPL
SCHEMBL21802111 0.81 ALPL (0.51) ALPLHTT
SCHEMBL21802040 0.81 ALPL (0.44) ALPL
SCHEMBL30538734 0.81 ALPL (0.55) ALPL
SCHEMBL21802036 0.80 ALPL (0.47) ALPLALDH1A1MAPK1HTTIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3559007-B1 SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY DAIICHI SANKYO CO LTD (JP) 2023-08-16 EP disclosed
US-11046710-B2 Sulfonamide compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-29 US disclosed
US-11014939-B2 2021-05-25 US disclosed
US-20200087321-A1 SULFONAMIDE COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087321-A1 SULFONAMIDE COMPOUNDS ALPI, ASAH2, STS ALPL 7/4885ALDH1A1 310/4885MAPK1 2193/4885
US-11014939-B2 ALPI, ALPP, ACER2 ALPL 5/4885ALDH1A1 177/4885MAPK1 2373/4885
US-11046710-B2 Sulfonamide compounds ALPI, ASAH2, STS ALPL 7/4885ALDH1A1 310/4885MAPK1 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.